Literature DB >> 16614792

Combination therapy of prednisolone and mizoribine improves cryoglobulinemic vasculitis with purpura and skin ulcers.

Masahide Hamaguchi1, Yutaka Kawahito, Yasunori Tsubouchi, Masataka Kohno, Aihiro Yamamoto, Hidetaka Ishino, Makoto Wada, Toshikazu Yoshikawa.   

Abstract

Conventional treatment is not standardized for hepatitis C virus-negative cryoglobulinemia, but corticosteroids, immunosuppressive agents, and plasma exchange typically improved the symptoms. Mizoribine is an immunosuppressive agent that was developed in Japan and has been found to inhibit the proliferation of lymphocytes, especially B cells. We have encountered an elder patient who had hepatitis C virus-negative, type II cryoglobulinemic vasculitis with leg purpura and skin ulcers. Her symptoms improved and cryoglobulin disappeared by the combination therapy of prednisolone and mizoribine. We speculate the action mechanism of this therapy is due to immunosuppressive effects including up-regulation of the efficacy of prednisolone by mizoribine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16614792     DOI: 10.1007/s10067-006-0295-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  16 in total

1.  Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression.

Authors:  K Tanabe; T Tokumoto; N Ishikawa; A Kanematsu; T Oshima; M Harano; M Inui; T Yagisawa; I Nakajima; S Fuchinoue; K Takahashi; H Toma
Journal:  Transplant Proc       Date:  1999-11       Impact factor: 1.066

2.  Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan.

Authors:  T Akiyama; H Okazaki; K Takahashi; A Hasegawa; K Tanabe; K Uchida; S Takahara; H Toma
Journal:  Transplant Proc       Date:  2005-03       Impact factor: 1.066

Review 3.  Cryoglobulins.

Authors:  C Ferri; A L Zignego; S A Pileri
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

4.  Effect of mizoribine on glomerulonephritis of early-stage IgA nephropathy in ddY mice.

Authors:  M Shimizu; I Shou; T Tsuge; M Abe; Y Tomino
Journal:  Nephron       Date:  1998       Impact factor: 2.847

5.  Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis.

Authors:  W Yumura; S Suganuma; K Uchida; T Moriyama; S Otsubo; T Takei; M Naito; M Koike; K Nitta; H Nihei
Journal:  Clin Nephrol       Date:  2005-07       Impact factor: 0.975

6.  Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome.

Authors:  K Saida; Z Zhigang; K Ozawa; T Konishi; T Saida
Journal:  Intern Med       Date:  1999-08       Impact factor: 1.271

7.  Mizoribine reduces urinary protein excretion in rats given puromycin aminonucleoside.

Authors:  T Shibasaki; H Matsuda; H Gomi; M Usui; F Ishimoto; O Sakai
Journal:  Am J Nephrol       Date:  1996       Impact factor: 3.754

Review 8.  Mizoribine: mode of action and effects in clinical use.

Authors:  Shumpei Yokota
Journal:  Pediatr Int       Date:  2002-04       Impact factor: 1.524

9.  A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey).

Authors:  Toshiaki Shibasaki; Akio Koyama; Akira Hishida; Eri Muso; Gengo Osawa; Hideaki Yamabe; Hideo Shiiki; Hirofumi Makino; Hiroshi Sato; Isao Ishikawa; Kenji Maeda; Kimio Tomita; Masaaki Arakawa; Masashi Ishida; Masashi Sato; Mitsumasa Nagase; Naoki Kashihara; Noriaki Yorioka; Takao Koike; Takao Saito; Takashi Harada; Tetsuya Mitarai; Tetsuzo Sugisaki; Toshihiko Nagasawa; Yasuhiko Tomino; Yoshihisa Nojima; Yutaka Kobayashi; Osamu Sakai
Journal:  Clin Exp Nephrol       Date:  2004-06       Impact factor: 2.801

10.  Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine.

Authors:  L A Turka; J Dayton; G Sinclair; C B Thompson; B S Mitchell
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

View more
  1 in total

1.  Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia.

Authors:  Yuka Kurokawa; Kiyomi Koike; Yusuke Kaida; Sakuya Ito; Hirotane Chiba; Kengo Urae; Tomofumi Moriyama; Nao Nakamura; Tetsurou Imai; Ryo Shibata; Takuma Hazama; Daisuke Wakasugi; Seiya Okuda; Kei Fukami
Journal:  CEN Case Rep       Date:  2019-03-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.